| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 35 | 2015 | 75 | 11.080 |
Why?
|
| Ventricular Dysfunction, Right | 25 | 2022 | 33 | 8.520 |
Why?
|
| Echocardiography | 26 | 2015 | 144 | 5.820 |
Why?
|
| Ventricular Function, Right | 19 | 2022 | 30 | 5.350 |
Why?
|
| Heart Ventricles | 18 | 2022 | 110 | 5.150 |
Why?
|
| Heart Failure | 11 | 2023 | 235 | 4.420 |
Why?
|
| Ventricular Dysfunction, Left | 14 | 2023 | 85 | 4.050 |
Why?
|
| Stroke Volume | 20 | 2023 | 89 | 3.500 |
Why?
|
| Echocardiography, Doppler | 16 | 2017 | 37 | 3.100 |
Why?
|
| Tricuspid Valve | 10 | 2017 | 12 | 2.670 |
Why?
|
| Cardiovascular Diseases | 11 | 2022 | 664 | 2.550 |
Why?
|
| Aortic Valve Stenosis | 5 | 2021 | 23 | 2.270 |
Why?
|
| Humans | 118 | 2024 | 37093 | 2.190 |
Why?
|
| Ventricular Function, Left | 12 | 2023 | 96 | 2.150 |
Why?
|
| Mitral Valve | 7 | 2020 | 19 | 1.970 |
Why?
|
| Middle Aged | 62 | 2019 | 10129 | 1.920 |
Why?
|
| Liver Transplantation | 4 | 2016 | 30 | 1.850 |
Why?
|
| Hypertension | 7 | 2023 | 796 | 1.820 |
Why?
|
| Pulmonary Embolism | 5 | 2013 | 32 | 1.710 |
Why?
|
| Echocardiography, Doppler, Color | 6 | 2012 | 12 | 1.680 |
Why?
|
| Image Interpretation, Computer-Assisted | 7 | 2015 | 61 | 1.680 |
Why?
|
| Elasticity Imaging Techniques | 4 | 2013 | 9 | 1.620 |
Why?
|
| Pulmonary Artery | 9 | 2013 | 31 | 1.590 |
Why?
|
| Coronavirus Infections | 3 | 2020 | 68 | 1.480 |
Why?
|
| Pneumonia, Viral | 3 | 2020 | 76 | 1.460 |
Why?
|
| Mouthwashes | 2 | 2020 | 6 | 1.460 |
Why?
|
| Female | 73 | 2021 | 20969 | 1.450 |
Why?
|
| Male | 69 | 2020 | 20025 | 1.440 |
Why?
|
| Mouth | 2 | 2020 | 45 | 1.420 |
Why?
|
| Echocardiography, Doppler, Pulsed | 5 | 2014 | 6 | 1.390 |
Why?
|
| Reproducibility of Results | 19 | 2015 | 935 | 1.380 |
Why?
|
| Aged | 40 | 2022 | 6741 | 1.320 |
Why?
|
| Nitric Oxide | 2 | 2020 | 316 | 1.220 |
Why?
|
| Ultrasonography | 13 | 2021 | 112 | 1.210 |
Why?
|
| Sensitivity and Specificity | 14 | 2015 | 562 | 1.180 |
Why?
|
| Cyclonic Storms | 2 | 2018 | 64 | 1.160 |
Why?
|
| Adult | 40 | 2021 | 11712 | 1.150 |
Why?
|
| Echocardiography, Transesophageal | 6 | 2008 | 20 | 1.140 |
Why?
|
| Coronary Artery Disease | 2 | 2024 | 142 | 1.100 |
Why?
|
| Systole | 9 | 2015 | 61 | 1.090 |
Why?
|
| Internship and Residency | 2 | 2018 | 125 | 1.080 |
Why?
|
| Aortic Valve | 2 | 2020 | 23 | 1.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2023 | 643 | 0.990 |
Why?
|
| Retrospective Studies | 17 | 2017 | 2026 | 0.990 |
Why?
|
| Severity of Illness Index | 13 | 2013 | 610 | 0.970 |
Why?
|
| Coronary Angiography | 1 | 2024 | 90 | 0.940 |
Why?
|
| Vascular Resistance | 3 | 2014 | 34 | 0.930 |
Why?
|
| Heart-Assist Devices | 2 | 2022 | 17 | 0.890 |
Why?
|
| Atrial Fibrillation | 3 | 2015 | 101 | 0.890 |
Why?
|
| Tricuspid Valve Insufficiency | 3 | 2013 | 12 | 0.870 |
Why?
|
| Heart Atria | 4 | 2015 | 26 | 0.870 |
Why?
|
| Chronic Disease | 11 | 2015 | 484 | 0.870 |
Why?
|
| Ventricular Outflow Obstruction | 2 | 2013 | 6 | 0.850 |
Why?
|
| Linear Models | 11 | 2017 | 275 | 0.850 |
Why?
|
| Metformin | 1 | 2023 | 65 | 0.840 |
Why?
|
| Blood Pressure | 6 | 2019 | 646 | 0.830 |
Why?
|
| Aged, 80 and over | 17 | 2019 | 2379 | 0.830 |
Why?
|
| Takotsubo Cardiomyopathy | 1 | 2022 | 12 | 0.830 |
Why?
|
| Heart Septum | 4 | 2014 | 6 | 0.820 |
Why?
|
| Aspirin | 1 | 2022 | 49 | 0.820 |
Why?
|
| Hematologic Neoplasms | 1 | 2021 | 16 | 0.810 |
Why?
|
| Myocardial Contraction | 7 | 2008 | 48 | 0.800 |
Why?
|
| Hypercholesterolemia | 2 | 2021 | 38 | 0.800 |
Why?
|
| Echocardiography, Stress | 4 | 2016 | 5 | 0.800 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 49 | 0.790 |
Why?
|
| Insulin Resistance | 1 | 2023 | 184 | 0.780 |
Why?
|
| Anticholesteremic Agents | 1 | 2021 | 23 | 0.770 |
Why?
|
| Air Pollution | 1 | 2021 | 60 | 0.740 |
Why?
|
| Ultrasonography, Doppler | 2 | 2011 | 6 | 0.740 |
Why?
|
| Professional Role | 1 | 2020 | 40 | 0.730 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2020 | 21 | 0.730 |
Why?
|
| Air Pollutants | 1 | 2021 | 94 | 0.720 |
Why?
|
| Pharmacists | 1 | 2020 | 53 | 0.720 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2020 | 36 | 0.710 |
Why?
|
| Ventricular Dysfunction | 2 | 2012 | 4 | 0.700 |
Why?
|
| Liver | 2 | 2013 | 479 | 0.700 |
Why?
|
| Ventricular Remodeling | 4 | 2021 | 57 | 0.690 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2020 | 52 | 0.690 |
Why?
|
| Anticoagulants | 2 | 2015 | 102 | 0.680 |
Why?
|
| Dobutamine | 4 | 2016 | 7 | 0.680 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 191 | 0.670 |
Why?
|
| Observer Variation | 9 | 2013 | 52 | 0.670 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 198 | 0.650 |
Why?
|
| Internal Medicine | 1 | 2018 | 24 | 0.620 |
Why?
|
| Asthma | 1 | 2022 | 380 | 0.610 |
Why?
|
| Primary Health Care | 1 | 2020 | 294 | 0.610 |
Why?
|
| Thrombosis | 4 | 2021 | 63 | 0.570 |
Why?
|
| Risk Factors | 13 | 2020 | 3562 | 0.570 |
Why?
|
| Hypoglycemic Agents | 3 | 2023 | 160 | 0.570 |
Why?
|
| Blood Flow Velocity | 4 | 2015 | 61 | 0.570 |
Why?
|
| Heart Neoplasms | 2 | 2014 | 7 | 0.560 |
Why?
|
| Bacteria | 1 | 2019 | 255 | 0.560 |
Why?
|
| Students, Medical | 1 | 2018 | 130 | 0.560 |
Why?
|
| Venous Thrombosis | 3 | 2021 | 28 | 0.560 |
Why?
|
| Time Factors | 9 | 2019 | 1742 | 0.550 |
Why?
|
| Myocarditis | 2 | 2013 | 20 | 0.530 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2015 | 3 | 0.530 |
Why?
|
| von Willebrand Diseases | 1 | 2015 | 2 | 0.520 |
Why?
|
| Angiodysplasia | 1 | 2015 | 3 | 0.520 |
Why?
|
| Analysis of Variance | 8 | 2013 | 550 | 0.520 |
Why?
|
| Patient Selection | 2 | 2015 | 164 | 0.520 |
Why?
|
| ADAM Proteins | 1 | 2015 | 16 | 0.510 |
Why?
|
| Clinical Trials as Topic | 2 | 2015 | 204 | 0.510 |
Why?
|
| Thyroid Crisis | 1 | 2015 | 1 | 0.510 |
Why?
|
| Pericardium | 2 | 2014 | 15 | 0.510 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2015 | 27 | 0.510 |
Why?
|
| Thromboembolism | 1 | 2015 | 13 | 0.510 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2020 | 13 | 0.500 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2022 | 62 | 0.500 |
Why?
|
| Hypertrophy, Right Ventricular | 1 | 2014 | 2 | 0.490 |
Why?
|
| Cardiac Surgical Procedures | 2 | 2005 | 48 | 0.480 |
Why?
|
| Electrocardiography | 4 | 2024 | 156 | 0.470 |
Why?
|
| Lung Transplantation | 1 | 2014 | 20 | 0.460 |
Why?
|
| Pericarditis | 1 | 2013 | 2 | 0.460 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2013 | 45 | 0.460 |
Why?
|
| Predictive Value of Tests | 7 | 2019 | 400 | 0.450 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 53 | 0.450 |
Why?
|
| United States | 12 | 2022 | 4223 | 0.450 |
Why?
|
| Arteriovenous Anastomosis | 1 | 2013 | 2 | 0.450 |
Why?
|
| Mammary Arteries | 1 | 2013 | 3 | 0.450 |
Why?
|
| Cardiotonic Agents | 3 | 2004 | 37 | 0.440 |
Why?
|
| Adenocarcinoma | 2 | 2014 | 251 | 0.440 |
Why?
|
| Algorithms | 2 | 2013 | 465 | 0.440 |
Why?
|
| Pilot Projects | 7 | 2018 | 661 | 0.440 |
Why?
|
| Prognosis | 4 | 2020 | 739 | 0.430 |
Why?
|
| ROC Curve | 5 | 2012 | 138 | 0.430 |
Why?
|
| Pulmonary Wedge Pressure | 3 | 2006 | 7 | 0.420 |
Why?
|
| Biomedical Research | 1 | 2017 | 400 | 0.420 |
Why?
|
| Acute Disease | 4 | 2013 | 147 | 0.410 |
Why?
|
| Exercise Test | 5 | 2015 | 67 | 0.410 |
Why?
|
| Myocardial Infarction | 2 | 2024 | 225 | 0.410 |
Why?
|
| Risk Assessment | 7 | 2019 | 753 | 0.410 |
Why?
|
| Heart Diseases | 2 | 2021 | 104 | 0.400 |
Why?
|
| Valsalva Maneuver | 1 | 2011 | 1 | 0.390 |
Why?
|
| Atrial Appendage | 2 | 2015 | 4 | 0.380 |
Why?
|
| Puerto Rico | 4 | 2019 | 1378 | 0.380 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2007 | 10 | 0.370 |
Why?
|
| Diastole | 5 | 2015 | 42 | 0.370 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 358 | 0.360 |
Why?
|
| Heart Rate | 4 | 2021 | 253 | 0.350 |
Why?
|
| Prospective Studies | 6 | 2013 | 1378 | 0.340 |
Why?
|
| Statistics as Topic | 5 | 2010 | 117 | 0.330 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2005 | 19 | 0.330 |
Why?
|
| Atrioventricular Node | 1 | 2008 | 3 | 0.320 |
Why?
|
| Ventricular Function | 1 | 2008 | 8 | 0.320 |
Why?
|
| Ticlopidine | 2 | 2018 | 15 | 0.310 |
Why?
|
| Treatment Outcome | 7 | 2021 | 1369 | 0.310 |
Why?
|
| Incidence | 2 | 2021 | 922 | 0.310 |
Why?
|
| Pulmonary Veins | 1 | 2007 | 6 | 0.300 |
Why?
|
| Thoracic Injuries | 1 | 2007 | 11 | 0.300 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2007 | 29 | 0.300 |
Why?
|
| Blood Platelets | 2 | 2018 | 77 | 0.290 |
Why?
|
| Fistula | 1 | 2005 | 1 | 0.270 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2005 | 1 | 0.270 |
Why?
|
| Pennsylvania | 3 | 2011 | 42 | 0.270 |
Why?
|
| Anemia, Sickle Cell | 1 | 2007 | 183 | 0.260 |
Why?
|
| Natriuretic Agents | 1 | 2005 | 3 | 0.260 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2005 | 17 | 0.260 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2005 | 21 | 0.260 |
Why?
|
| Troponin I | 1 | 2005 | 18 | 0.260 |
Why?
|
| Young Adult | 5 | 2014 | 4268 | 0.250 |
Why?
|
| Endocarditis | 1 | 2004 | 10 | 0.250 |
Why?
|
| Diagnosis, Differential | 4 | 2013 | 217 | 0.250 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2004 | 41 | 0.250 |
Why?
|
| Mitral Valve Prolapse | 1 | 2004 | 1 | 0.240 |
Why?
|
| Heart Valves | 1 | 2004 | 2 | 0.240 |
Why?
|
| Candidiasis | 1 | 2004 | 84 | 0.240 |
Why?
|
| Hospice Care | 1 | 2004 | 15 | 0.230 |
Why?
|
| Hospital Mortality | 3 | 2020 | 187 | 0.230 |
Why?
|
| Cohort Studies | 3 | 2014 | 1492 | 0.230 |
Why?
|
| Coronary Artery Bypass | 1 | 2004 | 43 | 0.230 |
Why?
|
| Enoxaparin | 1 | 2003 | 2 | 0.230 |
Why?
|
| Palliative Care | 1 | 2004 | 49 | 0.230 |
Why?
|
| Multivariate Analysis | 4 | 2017 | 583 | 0.230 |
Why?
|
| Renal Insufficiency | 1 | 2003 | 18 | 0.220 |
Why?
|
| Logistic Models | 3 | 2017 | 923 | 0.220 |
Why?
|
| Sodium | 1 | 2023 | 103 | 0.210 |
Why?
|
| Needs Assessment | 1 | 2004 | 170 | 0.210 |
Why?
|
| Cardiomegaly | 1 | 2002 | 41 | 0.210 |
Why?
|
| Body Mass Index | 2 | 2013 | 854 | 0.210 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2021 | 2 | 0.210 |
Why?
|
| Case-Control Studies | 5 | 2013 | 1130 | 0.200 |
Why?
|
| Prevalence | 4 | 2015 | 1455 | 0.200 |
Why?
|
| Catheter-Related Infections | 1 | 2021 | 11 | 0.200 |
Why?
|
| Glucose | 1 | 2023 | 230 | 0.190 |
Why?
|
| Insulin | 1 | 2023 | 236 | 0.190 |
Why?
|
| Pharmaceutical Preparations | 1 | 2022 | 75 | 0.190 |
Why?
|
| Particulate Matter | 1 | 2021 | 51 | 0.190 |
Why?
|
| Trust | 1 | 2022 | 133 | 0.190 |
Why?
|
| Reference Values | 2 | 2013 | 212 | 0.190 |
Why?
|
| Kidney | 1 | 2003 | 337 | 0.190 |
Why?
|
| Lipids | 1 | 2022 | 235 | 0.190 |
Why?
|
| Earthquakes | 1 | 2020 | 7 | 0.180 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 56 | 0.180 |
Why?
|
| Renal Dialysis | 1 | 2021 | 120 | 0.180 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 97 | 0.180 |
Why?
|
| Saliva | 1 | 2020 | 107 | 0.170 |
Why?
|
| Health Status Indicators | 2 | 2009 | 75 | 0.170 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 47 | 0.170 |
Why?
|
| Environmental Exposure | 1 | 2021 | 216 | 0.170 |
Why?
|
| Sterol Esterase | 2 | 1996 | 3 | 0.160 |
Why?
|
| Obesity | 2 | 2023 | 1067 | 0.160 |
Why?
|
| Pancreas | 2 | 1996 | 35 | 0.160 |
Why?
|
| Heart Function Tests | 2 | 2008 | 11 | 0.160 |
Why?
|
| Tetrazoles | 1 | 2018 | 49 | 0.150 |
Why?
|
| Hemodynamics | 2 | 2009 | 91 | 0.150 |
Why?
|
| Ventricular Pressure | 2 | 2008 | 7 | 0.140 |
Why?
|
| Drug Resistance | 1 | 2017 | 99 | 0.140 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 885 | 0.140 |
Why?
|
| Cholesterol Esters | 1 | 1996 | 5 | 0.140 |
Why?
|
| Cholesterol, Dietary | 1 | 1996 | 10 | 0.140 |
Why?
|
| Intestinal Absorption | 1 | 1996 | 20 | 0.140 |
Why?
|
| Aneurysm | 1 | 1995 | 6 | 0.140 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 560 | 0.130 |
Why?
|
| Blood Gas Monitoring, Transcutaneous | 1 | 2015 | 1 | 0.130 |
Why?
|
| Pulse | 1 | 2015 | 4 | 0.130 |
Why?
|
| Research Personnel | 1 | 2017 | 155 | 0.130 |
Why?
|
| Ultrasonography, Doppler, Duplex | 1 | 2015 | 6 | 0.130 |
Why?
|
| Probability | 2 | 2008 | 78 | 0.130 |
Why?
|
| Angiography | 1 | 2015 | 15 | 0.130 |
Why?
|
| Extremities | 1 | 2015 | 18 | 0.130 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 494 | 0.130 |
Why?
|
| New York | 3 | 2004 | 71 | 0.130 |
Why?
|
| Ecchymosis | 1 | 2015 | 1 | 0.130 |
Why?
|
| von Willebrand Factor | 1 | 2015 | 5 | 0.130 |
Why?
|
| Blood Pressure Determination | 1 | 2015 | 52 | 0.130 |
Why?
|
| Treatment Refusal | 1 | 2015 | 20 | 0.130 |
Why?
|
| Shear Strength | 1 | 2015 | 25 | 0.130 |
Why?
|
| Syndrome | 1 | 2015 | 74 | 0.130 |
Why?
|
| Protein Structure, Quaternary | 1 | 2015 | 64 | 0.130 |
Why?
|
| Protein Stability | 1 | 2015 | 45 | 0.130 |
Why?
|
| Scleroderma, Systemic | 1 | 2015 | 11 | 0.130 |
Why?
|
| Organ Size | 1 | 2015 | 157 | 0.130 |
Why?
|
| Physicians | 1 | 2017 | 163 | 0.120 |
Why?
|
| Vasodilator Agents | 1 | 2015 | 56 | 0.120 |
Why?
|
| Contrast Media | 1 | 2015 | 92 | 0.120 |
Why?
|
| Infusions, Intravenous | 3 | 2004 | 47 | 0.120 |
Why?
|
| Demography | 1 | 2015 | 175 | 0.120 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2015 | 27 | 0.120 |
Why?
|
| Diabetic Nephropathies | 1 | 2015 | 61 | 0.120 |
Why?
|
| Colonoscopy | 1 | 2015 | 104 | 0.120 |
Why?
|
| Social Behavior | 1 | 2015 | 131 | 0.120 |
Why?
|
| Culture | 1 | 2015 | 173 | 0.120 |
Why?
|
| Enzyme Activation | 1 | 2015 | 444 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2015 | 481 | 0.120 |
Why?
|
| Exercise Tolerance | 1 | 2013 | 15 | 0.120 |
Why?
|
| Adolescent | 3 | 2014 | 5363 | 0.120 |
Why?
|
| Waiting Lists | 1 | 2013 | 36 | 0.120 |
Why?
|
| Colchicine | 1 | 2013 | 15 | 0.110 |
Why?
|
| Tubulin Modulators | 1 | 2013 | 18 | 0.110 |
Why?
|
| Ohio | 1 | 2013 | 14 | 0.110 |
Why?
|
| Incidental Findings | 1 | 2013 | 10 | 0.110 |
Why?
|
| Milrinone | 2 | 2004 | 4 | 0.110 |
Why?
|
| Radiography | 1 | 2013 | 72 | 0.110 |
Why?
|
| Image Enhancement | 1 | 2013 | 40 | 0.110 |
Why?
|
| Preoperative Care | 1 | 2012 | 26 | 0.110 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2013 | 121 | 0.100 |
Why?
|
| Double-Blind Method | 2 | 2004 | 286 | 0.100 |
Why?
|
| Phenotype | 1 | 2014 | 689 | 0.100 |
Why?
|
| Constriction, Pathologic | 1 | 2011 | 6 | 0.100 |
Why?
|
| Epoprostenol | 1 | 2011 | 25 | 0.100 |
Why?
|
| Physical Exertion | 1 | 2011 | 26 | 0.100 |
Why?
|
| Sulfonamides | 1 | 2011 | 80 | 0.090 |
Why?
|
| Chi-Square Distribution | 2 | 2017 | 225 | 0.090 |
Why?
|
| Giant Cells | 1 | 2008 | 13 | 0.080 |
Why?
|
| Reference Standards | 1 | 2008 | 52 | 0.080 |
Why?
|
| Stroke | 1 | 2012 | 286 | 0.080 |
Why?
|
| Regression Analysis | 1 | 2010 | 455 | 0.080 |
Why?
|
| Quality of Life | 2 | 2004 | 481 | 0.080 |
Why?
|
| Antihypertensive Agents | 1 | 2011 | 284 | 0.080 |
Why?
|
| Dilatation, Pathologic | 1 | 2007 | 9 | 0.080 |
Why?
|
| Platelet Function Tests | 2 | 2018 | 7 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2019 | 291 | 0.080 |
Why?
|
| Pacemaker, Artificial | 1 | 2007 | 17 | 0.080 |
Why?
|
| Age Factors | 2 | 2013 | 1033 | 0.070 |
Why?
|
| Heart | 1 | 2008 | 180 | 0.070 |
Why?
|
| Pericarditis, Constrictive | 1 | 2006 | 1 | 0.070 |
Why?
|
| Vena Cava, Superior | 1 | 2005 | 4 | 0.070 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2007 | 173 | 0.070 |
Why?
|
| Myxoma | 1 | 2005 | 5 | 0.070 |
Why?
|
| Rare Diseases | 1 | 2005 | 13 | 0.070 |
Why?
|
| Disease Progression | 1 | 2007 | 601 | 0.060 |
Why?
|
| Tibia | 1 | 2005 | 18 | 0.060 |
Why?
|
| Pericardiocentesis | 1 | 2004 | 2 | 0.060 |
Why?
|
| Immunocompromised Host | 1 | 2004 | 22 | 0.060 |
Why?
|
| Body Height | 1 | 2005 | 53 | 0.060 |
Why?
|
| Diabetes Complications | 1 | 2005 | 90 | 0.060 |
Why?
|
| Terminally Ill | 1 | 2004 | 3 | 0.060 |
Why?
|
| Comorbidity | 1 | 2006 | 623 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 143 | 0.060 |
Why?
|
| Factor Xa | 1 | 2003 | 3 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2018 | 227 | 0.060 |
Why?
|
| Kidney Function Tests | 1 | 2003 | 29 | 0.060 |
Why?
|
| Long QT Syndrome | 1 | 2003 | 13 | 0.060 |
Why?
|
| Ambulatory Care | 1 | 2004 | 75 | 0.060 |
Why?
|
| Pulmonary Valve Stenosis | 2 | 2008 | 3 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2002 | 108 | 0.050 |
Why?
|
| Suppuration | 1 | 2021 | 3 | 0.050 |
Why?
|
| Sex Factors | 1 | 2005 | 898 | 0.050 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2021 | 5 | 0.050 |
Why?
|
| Drainage | 1 | 2021 | 11 | 0.050 |
Why?
|
| Cerebral Infarction | 1 | 2021 | 17 | 0.050 |
Why?
|
| Patient Participation | 1 | 2002 | 75 | 0.050 |
Why?
|
| Medicare | 1 | 2022 | 195 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2020 | 94 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2018 | 2721 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2004 | 404 | 0.040 |
Why?
|
| Data Collection | 1 | 2020 | 194 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2015 | 974 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2019 | 24 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 276 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2021 | 233 | 0.040 |
Why?
|
| Hospitalization | 1 | 2022 | 388 | 0.040 |
Why?
|
| Inpatients | 1 | 2019 | 74 | 0.040 |
Why?
|
| Aryldialkylphosphatase | 1 | 2018 | 10 | 0.040 |
Why?
|
| Length of Stay | 1 | 2019 | 185 | 0.040 |
Why?
|
| Postoperative Complications | 1 | 2019 | 210 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2018 | 177 | 0.040 |
Why?
|
| Diet, Atherogenic | 1 | 1996 | 6 | 0.030 |
Why?
|
| Bioprosthesis | 1 | 1995 | 5 | 0.030 |
Why?
|
| Enzyme Induction | 1 | 1996 | 53 | 0.030 |
Why?
|
| Heart Valve Prosthesis | 1 | 1995 | 18 | 0.030 |
Why?
|
| Arteriosclerosis | 1 | 1996 | 36 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 534 | 0.030 |
Why?
|
| Random Allocation | 1 | 1996 | 139 | 0.030 |
Why?
|
| Rabbits | 1 | 1996 | 283 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 1996 | 502 | 0.030 |
Why?
|
| Cholesterol | 1 | 1996 | 205 | 0.030 |
Why?
|
| Colonic Neoplasms | 1 | 1996 | 186 | 0.030 |
Why?
|
| Confidence Intervals | 1 | 2013 | 149 | 0.030 |
Why?
|
| Brain | 1 | 2021 | 1346 | 0.030 |
Why?
|
| Anthropometry | 1 | 2013 | 97 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 1996 | 1207 | 0.020 |
Why?
|
| DNA | 1 | 1992 | 574 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 2008 | 14 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2008 | 60 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2008 | 27 | 0.020 |
Why?
|
| Connective Tissue Diseases | 1 | 2008 | 5 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2008 | 88 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2008 | 893 | 0.020 |
Why?
|
| Research Design | 1 | 2007 | 313 | 0.020 |
Why?
|
| Health Education | 1 | 2007 | 338 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 2003 | 75 | 0.010 |
Why?
|
| Animals | 1 | 1996 | 15081 | 0.010 |
Why?
|
| Restriction Mapping | 1 | 1992 | 45 | 0.010 |
Why?
|
| Protein Sorting Signals | 1 | 1992 | 26 | 0.010 |
Why?
|
| DNA Probes | 1 | 1992 | 29 | 0.010 |
Why?
|
| Nucleic Acid Hybridization | 1 | 1992 | 69 | 0.010 |
Why?
|
| RNA Splicing | 1 | 1992 | 40 | 0.010 |
Why?
|
| Introns | 1 | 1992 | 75 | 0.010 |
Why?
|
| Exons | 1 | 1992 | 88 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1992 | 133 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1992 | 325 | 0.010 |
Why?
|
| Base Sequence | 1 | 1992 | 997 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 1992 | 515 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 1992 | 1568 | 0.010 |
Why?
|